Trends in Surgical Aortic Valve Replacement in More Than 3,000 Consecutive Cases in the Era of Transcatheter Aortic Valve Implantations

Miriam Silaschi; Lenard Conradi; Hendrik Treede; Beate Reiter; Ulrich Schaefer; Stefan Blankenberg; Hermann Reichenspurner

doi:10.1055/s-0035-1564615

Trends in Surgical Aortic Valve Replacement in More Than 3,000 Consecutive Cases in the Era of Transcatheter Aortic Valve Implantations

Standard

Trends in Surgical Aortic Valve Replacement in More Than 3,000 Consecutive Cases in the Era of Transcatheter Aortic Valve Implantations. / Silaschi, Miriam; Conradi, Lenard ; Treede, Hendrik ; Reiter, Beate; Schaefer, Ulrich; Blankenberg, Stefan ; Reichenspurner, Hermann.

In: THORAC CARDIOV SURG, Vol. 64, No. 5, 08.2016, p. 382-389.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Silaschi, M, Conradi, L , Treede, H , Reiter, B, Schaefer, U, Blankenberg, S & Reichenspurner, H 2016, 'Trends in Surgical Aortic Valve Replacement in More Than 3,000 Consecutive Cases in the Era of Transcatheter Aortic Valve Implantations', THORAC CARDIOV SURG, vol. 64, no. 5, pp. 382-389. https://doi.org/10.1055/s-0035-1564615

APA

Silaschi, M., Conradi, L., Treede, H., Reiter, B., Schaefer, U., Blankenberg, S., & Reichenspurner, H. (2016). Trends in Surgical Aortic Valve Replacement in More Than 3,000 Consecutive Cases in the Era of Transcatheter Aortic Valve Implantations. THORAC CARDIOV SURG, 64(5), 382-389. https://doi.org/10.1055/s-0035-1564615

Vancouver

Silaschi M, Conradi L , Treede H , Reiter B, Schaefer U, Blankenberg S et al. Trends in Surgical Aortic Valve Replacement in More Than 3,000 Consecutive Cases in the Era of Transcatheter Aortic Valve Implantations. THORAC CARDIOV SURG. 2016 Aug;64(5):382-389. https://doi.org/10.1055/s-0035-1564615

Bibtex

@article{54c4ab9f4f1646f286923f0cd57758b4,

title = "Trends in Surgical Aortic Valve Replacement in More Than 3,000 Consecutive Cases in the Era of Transcatheter Aortic Valve Implantations",

abstract = "Objectives Biological prostheses for surgical aortic valve replacement (sAVR) are increasingly being considered in patients < 60 years of age. Likely, preserving the option of performing a transcatheter valve-in-valve (ViV) procedure in cases of structural valve deterioration has contributed to this development. We assessed the use pattern in sAVR over an 11-year period. Methods From 2002 through 2012, a total of 3,172 patients underwent sAVR at our center. Results Mean age was 70.4 ± 10.6 years and mortality was 1.9%. From 2002 to 2012, mean manufacturer given valve size increased from 22.8 ± 1.7 to 23.9 ± 2.0 mm (p < 0.001). Mean true internal diameter and effective orifice area increased from 19.6 to 20.3 mm (p = 0.027) and 1.41 to 1.56 cm(2) (p < 0.001), respectively. Use of mechanical valves decreased from 10.9 to 1.8% (p < 0.001), and patients were younger in 2012 than in 2002 (52.8 ± 16.5 vs. 41.0 ± 14.3 years; p = 0.028). Conclusion Profound change of use pattern in sAVR was observed as indication for biological prostheses became more liberal. Larger prostheses were implanted during the observational period. Especially in younger patients, optimal sizing is essential to preserve the option for subsequent ViV procedures. ",

keywords = "Age Factors, Aged, Aged, 80 and over, Aortic Valve/diagnostic imaging, Aortic Valve Stenosis/diagnostic imaging, Bioprosthesis/trends, Databases, Factual, Female, Germany, Heart Valve Prosthesis/trends, Heart Valve Prosthesis Implantation/adverse effects, Humans, Male, Middle Aged, Patient Selection, Practice Patterns, Physicians'/trends, Prosthesis Design, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome",

author = "Miriam Silaschi and Lenard Conradi and Hendrik Treede and Beate Reiter and Ulrich Schaefer and Stefan Blankenberg and Hermann Reichenspurner",

note = "Georg Thieme Verlag KG Stuttgart · New York.",

year = "2016",

month = aug,

doi = "10.1055/s-0035-1564615",

language = "English",

volume = "64",

pages = "382--389",

journal = "THORAC CARDIOV SURG",

issn = "0171-6425",

publisher = "Georg Thieme Verlag KG",

number = "5",

}

RIS

TY - JOUR

T1 - Trends in Surgical Aortic Valve Replacement in More Than 3,000 Consecutive Cases in the Era of Transcatheter Aortic Valve Implantations

AU - Silaschi, Miriam

AU - Conradi, Lenard

AU - Treede, Hendrik

AU - Reiter, Beate

AU - Schaefer, Ulrich

AU - Blankenberg, Stefan

AU - Reichenspurner, Hermann

N1 - Georg Thieme Verlag KG Stuttgart · New York.

PY - 2016/8

Y1 - 2016/8

N2 - Objectives Biological prostheses for surgical aortic valve replacement (sAVR) are increasingly being considered in patients < 60 years of age. Likely, preserving the option of performing a transcatheter valve-in-valve (ViV) procedure in cases of structural valve deterioration has contributed to this development. We assessed the use pattern in sAVR over an 11-year period. Methods From 2002 through 2012, a total of 3,172 patients underwent sAVR at our center. Results Mean age was 70.4 ± 10.6 years and mortality was 1.9%. From 2002 to 2012, mean manufacturer given valve size increased from 22.8 ± 1.7 to 23.9 ± 2.0 mm (p < 0.001). Mean true internal diameter and effective orifice area increased from 19.6 to 20.3 mm (p = 0.027) and 1.41 to 1.56 cm(2) (p < 0.001), respectively. Use of mechanical valves decreased from 10.9 to 1.8% (p < 0.001), and patients were younger in 2012 than in 2002 (52.8 ± 16.5 vs. 41.0 ± 14.3 years; p = 0.028). Conclusion Profound change of use pattern in sAVR was observed as indication for biological prostheses became more liberal. Larger prostheses were implanted during the observational period. Especially in younger patients, optimal sizing is essential to preserve the option for subsequent ViV procedures.

AB - Objectives Biological prostheses for surgical aortic valve replacement (sAVR) are increasingly being considered in patients < 60 years of age. Likely, preserving the option of performing a transcatheter valve-in-valve (ViV) procedure in cases of structural valve deterioration has contributed to this development. We assessed the use pattern in sAVR over an 11-year period. Methods From 2002 through 2012, a total of 3,172 patients underwent sAVR at our center. Results Mean age was 70.4 ± 10.6 years and mortality was 1.9%. From 2002 to 2012, mean manufacturer given valve size increased from 22.8 ± 1.7 to 23.9 ± 2.0 mm (p < 0.001). Mean true internal diameter and effective orifice area increased from 19.6 to 20.3 mm (p = 0.027) and 1.41 to 1.56 cm(2) (p < 0.001), respectively. Use of mechanical valves decreased from 10.9 to 1.8% (p < 0.001), and patients were younger in 2012 than in 2002 (52.8 ± 16.5 vs. 41.0 ± 14.3 years; p = 0.028). Conclusion Profound change of use pattern in sAVR was observed as indication for biological prostheses became more liberal. Larger prostheses were implanted during the observational period. Especially in younger patients, optimal sizing is essential to preserve the option for subsequent ViV procedures.

KW - Age Factors

KW - Aged

KW - Aged, 80 and over

KW - Aortic Valve/diagnostic imaging

KW - Aortic Valve Stenosis/diagnostic imaging

KW - Bioprosthesis/trends

KW - Databases, Factual

KW - Female

KW - Germany

KW - Heart Valve Prosthesis/trends

KW - Heart Valve Prosthesis Implantation/adverse effects

KW - Humans

KW - Male

KW - Middle Aged

KW - Patient Selection

KW - Practice Patterns, Physicians'/trends

KW - Prosthesis Design

KW - Retrospective Studies

KW - Risk Factors

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1055/s-0035-1564615

DO - 10.1055/s-0035-1564615

M3 - SCORING: Journal article

C2 - 26444659

VL - 64

SP - 382

EP - 389

JO - THORAC CARDIOV SURG

JF - THORAC CARDIOV SURG

SN - 0171-6425

IS - 5

ER -